Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$53.93
+0.7%
$54.04
$39.97
$72.83
$10.20B0.952.57 million shs533,008 shs
Icon Plc stock logo
ICLR
Icon
$148.83
-1.8%
$139.97
$125.10
$347.72
$12.05B1.171.10 million shs201,877 shs
Incyte Corporation stock logo
INCY
Incyte
$68.31
+0.9%
$65.82
$53.56
$83.95
$13.25B0.681.96 million shs249,535 shs
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$160.93
-2.2%
$151.34
$134.65
$252.88
$27.86B1.31.65 million shs186,788 shs
PPD, Inc. stock logo
PPD
PPD
$47.28
$47.27
$31.54
$47.41
$16.61B1.961.91 million shsN/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
+2.02%-1.94%-2.42%+17.67%+18.48%
Icon Plc stock logo
ICLR
Icon
+2.70%+1.81%+8.96%-2.51%-52.77%
Incyte Corporation stock logo
INCY
Incyte
+0.59%-1.54%-1.60%+14.97%+16.33%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
+1.30%+1.32%+8.30%+4.88%-21.18%
PPD, Inc. stock logo
PPD
PPD
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
4.9341 of 5 stars
4.55.00.04.73.52.50.6
Icon Plc stock logo
ICLR
Icon
4.3596 of 5 stars
4.33.00.00.01.93.32.5
Incyte Corporation stock logo
INCY
Incyte
4.7656 of 5 stars
3.13.00.02.82.63.33.1
IQVIA Holdings Inc. stock logo
IQV
IQVIA
4.8943 of 5 stars
4.42.00.04.62.91.72.5
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
2.95
Moderate Buy$70.5030.73% Upside
Icon Plc stock logo
ICLR
Icon
2.60
Moderate Buy$198.0833.09% Upside
Incyte Corporation stock logo
INCY
Incyte
2.22
Hold$74.539.12% Upside
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.75
Moderate Buy$222.4538.23% Upside
PPD, Inc. stock logo
PPD
PPD
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest IQV, INCY, EXAS, PPD, and ICLR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Icon Plc stock logo
ICLR
Icon
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$155.00 ➝ $170.00
7/9/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$170.00 ➝ $180.00
7/8/2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.00
6/24/2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.00
6/23/2025
Incyte Corporation stock logo
INCY
Incyte
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetSector Perform ➝ Sector Perform$67.00
6/16/2025
Incyte Corporation stock logo
INCY
Incyte
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$75.00 ➝ $107.00
6/3/2025
Incyte Corporation stock logo
INCY
Incyte
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/3/2025
Incyte Corporation stock logo
INCY
Incyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$61.00
5/27/2025
Incyte Corporation stock logo
INCY
Incyte
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$72.00 ➝ $73.00
5/23/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$188.00
5/22/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$2.76B3.69$5.79 per share9.32$12.98 per share4.15
Icon Plc stock logo
ICLR
Icon
$8.28B1.45$20.22 per share7.36$117.92 per share1.26
Incyte Corporation stock logo
INCY
Incyte
$4.24B3.12$0.56 per share121.51$17.90 per share3.82
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$15.41B1.81$16.46 per share9.78$33.43 per share4.81
PPD, Inc. stock logo
PPD
PPD
$4.68B3.55$1.99 per share23.71($1.21) per share-39.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$1.03B-$5.51N/A107.8611.21-36.06%-3.75%-1.68%7/30/2025 (Estimated)
Icon Plc stock logo
ICLR
Icon
$791.47M$9.1816.269.731.819.25%11.46%6.49%7/23/2025 (Estimated)
Incyte Corporation stock logo
INCY
Incyte
$32.62M$0.32213.8810.440.570.48%2.77%1.77%7/29/2025 (Estimated)
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$1.37B$7.3421.9413.191.808.61%29.16%6.96%7/22/2025 (Estimated)
PPD, Inc. stock logo
PPD
PPD
$153.69M$1.0047.2825.982.116.11%-89.48%7.94%N/A

Latest IQV, INCY, EXAS, PPD, and ICLR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$0.04N/AN/AN/A$774.43 millionN/A
7/29/2025Q2 2025
Incyte Corporation stock logo
INCY
Incyte
$1.38N/AN/AN/A$1.15 billionN/A
7/23/2025Q2 2025
Icon Plc stock logo
ICLR
Icon
$3.18N/AN/AN/A$1.98 billionN/A
7/22/2025Q2 2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$2.76N/AN/AN/A$3.96 billionN/A
5/6/2025Q1 2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$2.63$2.70+$0.07$1.40$3.77 billion$3.83 billion
5/1/2025Q1 2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 million
4/30/2025Q1 2025
Icon Plc stock logo
ICLR
Icon
$3.17$3.19+$0.02$1.90$2.03 billion$2.00 billion
4/29/2025Q1 2025
Incyte Corporation stock logo
INCY
Incyte
$1.01$1.16+$0.15$0.80$996.17 million$1.05 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
IQVIA Holdings Inc. stock logo
IQV
IQVIA
N/AN/AN/AN/AN/A
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.97
2.73
2.38
Icon Plc stock logo
ICLR
Icon
0.36
1.27
1.27
Incyte Corporation stock logo
INCY
Incyte
0.01
2.04
2.00
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.19
0.82
0.82
PPD, Inc. stock logo
PPD
PPD
N/A
1.23
1.23

Institutional Ownership

CompanyInstitutional Ownership
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
88.82%
Icon Plc stock logo
ICLR
Icon
95.61%
Incyte Corporation stock logo
INCY
Incyte
96.97%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
89.62%
PPD, Inc. stock logo
PPD
PPD
87.82%

Insider Ownership

CompanyInsider Ownership
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.20%
Icon Plc stock logo
ICLR
Icon
44.00%
Incyte Corporation stock logo
INCY
Incyte
17.80%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
1.60%
PPD, Inc. stock logo
PPD
PPD
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
7,000188.64 million186.37 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,617193.57 million159.12 millionOptionable
IQVIA Holdings Inc. stock logo
IQV
IQVIA
88,000173.00 million170.23 millionOptionable
PPD, Inc. stock logo
PPD
PPD
26,000351.40 million344.72 millionNot Optionable

Recent News About These Companies

69-year-old man missing in Portsmouth: PPD
Crash shuts down TN highway

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Exact Sciences stock logo

Exact Sciences NASDAQ:EXAS

$53.93 +0.39 (+0.72%)
As of 11:17 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Icon stock logo

Icon NASDAQ:ICLR

$148.83 -2.75 (-1.81%)
As of 11:17 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Incyte stock logo

Incyte NASDAQ:INCY

$68.31 +0.64 (+0.94%)
As of 11:17 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

IQVIA stock logo

IQVIA NYSE:IQV

$160.93 -3.54 (-2.15%)
As of 11:17 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

PPD stock logo

PPD NASDAQ:PPD

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.